1. Insights
  2. Blogs
  3. Eye on FDA

Three Questions with Sedgwick’s Jeremy Schutz

December 4, 2024Three Questions

Reading Time : 2 min

By: Nathan A. Brown

In this edition of Three Questions, health care & life sciences partner Nate Brown spoke with Jeremy Schutz, director of business development, recall & remediation at Sedgwick, to explore key strategies that pharmaceutical companies and medical device manufacturers can adopt to mitigate risks related to supply chain disruptions, cybersecurity threats and increased FDA enforcement of quality control and compliance.

Sedgwick is the world’s leading expert in product recall and remediation spanning over 7,000 recalls, in 100 countries, and 50 languages.

What operational strategies can pharmaceutical companies adopt to mitigate the risks of supply chain disruptions?

In 2024, supply chain disruptions continue to be a significant risk for pharmaceutical companies, especially in the context of global component and ingredient shortages and transportation challenges. Companies should adopt a risk-based approach by diversifying their supplier base, investing in domestic production and building stronger supplier relationships to improve resilience. Real-time supply chain monitoring through digital tools like blockchain can help companies track and predict potential bottlenecks. For 2025, stakeholders should watch for increased regulatory pressure from the FDA to ensure supply chain transparency and resilience, particularly for essential drugs and devices critical to patient health.

How can medical device manufacturers minimize the risk of cybersecurity threats?

With the FDA’s new and stricter cybersecurity regulations, medical device manufacturers face increased risks. Manufacturers must integrate cybersecurity protocols early in the product development process, ensuring compliance with FDA guidelines for cybersecurity risk management. This includes secure software development, regular updates, vulnerability monitoring and patch management. Manufacturers should also establish post-market cybersecurity monitoring programs. Looking ahead to 2025, the FDA is expected to intensify its focus on artificial intelligence (AI)-driven medical devices and cybersecurity for wearables, which will require manufacturers to maintain a proactive cybersecurity strategy to prevent costly disruptions and recalls.

How can life sciences companies mitigate the risks associated with increased FDA enforcement of quality control and compliance?

In 2024, the FDA has ramped up inspections and enforcement actions, especially related to quality control in manufacturing processes for both pharmaceuticals and medical devices. To mitigate risks, companies should implement continuous quality improvement (CQI) processes, ensuring that manufacturing standards meet Good Manufacturing Practices (GMP) and FDA regulations. This includes regular internal audits, employee training on compliance and investing in digital quality management systems (QMS) that provide real-time monitoring and documentation of production processes. As we approach 2025, companies should anticipate more FDA scrutiny on data integrity and digital record-keeping, making it essential to maintain robust data security and transparency throughout the product lifecycle.

Share This Insight

Categories

Cybersecurity, Privacy & Data ProtectionMedical DevicesHealth CareArtificial IntelligenceHealth Information Privacy & SecurityFood and Drug Administration (FDA)AI/ML DevicesSupply Chain FDA EnforcementEnforcement
Subscribe to the Eye on FDA Blog Series >

Previous Entries

Eye on FDA

April 1, 2026

On March 30, 2026, the Food and Drug Administration (FDA) published a final guidance entitled “Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle.” The guidance provides updated recommendations to industry and FDA on how and when voluntary patient preference information (PPI) may be considered by FDA staff in decision making relating to devices. PPI is not required for FDA’s consideration as part of FDA decision making, but FDA may find it valuable to consider patient viewpoints when the information meets applicable legal requirements. In addition, FDA encourages industry and other interested parties to consider patient experience data in device development and evaluation, including data relating to patient preferences for outcomes and treatments. FDA acknowledges that patient perspective and personal experiences can help FDA evaluate the benefit-risk profile of certain devices throughout the total product life cycle.

...

Read More

Eye on FDA

March 24, 2026

On March 20, 2026, the Food and Drug Administration (FDA) announced the agency will hold a public hearing on the Commissioner’s National Priority Voucher (CNPV) Pilot Program, with a Federal Register notice soliciting public comment and scheduling a public hearing for June 12, 2026. As previously noted here and here, the program was announced in June 2025 for the purpose of providing select sponsors with a nontransferable voucher for enhanced engagement with FDA and expedited review for drugs and biologics supporting one or more critical national health priorities, while maintaining adherence to the law’s rigorous safety and effectiveness standards. The national health priorities include public health crisis response, innovative breakthrough therapies, large unmet medical needs, onshoring and supply chain resilience initiatives, and affordability improvements. To date, FDA has issued 18 Commissioner’s National Priority vouchers and approved four products to receive these vouchers, including two oncology drugs 44 and 55 days after filing.

...

Read More

Eye on FDA

March 20, 2026

On March 18, 2026, the Food and Drug Administration (FDA) issued draft guidance entitled “General Considerations for the Use of New Approach Methodologies in Drug Development.” The guidance is meant to provide drug developers with a validation framework and general recommendations for using new approach methodologies (NAMs) in drug development. The use of NAMs can improve predictive toxicology in humans and reduce reliance on animal testing.

...

Read More

Eye on FDA

March 16, 2026

On March 9, 2026, the Food and Drug Administration (FDA) published a draft guidance, “Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection.” The guidance is intended for foreign and domestic human and animal drug establishments manufacturing drugs regulated by the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER) and the Center for Veterinary Medicine (CVM). The guidance is also intended for combination product manufacturers for which CDER or CBER is the lead center.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.